GENERAL INFORMATION

Accommodations

The conference participants will be staying at the Aldemar: Knossos Royal Village (A' class), which is located in Hersonissos, 25 km from the airport.

Breakfast

Breakfast will be served at your hotel during the hours scheduled in this program.

 

Conference Venue

The Aldemar: Knossos Royal Village Conference Center is located at the hotel. 

 

Oral Presentations

An LCD projector and an overhead projector will be available for the oral presentations. Speakers are asked to bring their USB flash drive or CD to the conference reception desk at least 30 minutes prior to the session.  The allocated time for all presentations, unless otherwise indicated, includes five minutes Q&A.

 

Posters

Posters should be mounted Monday morning, May 29, on the designated boards and dismounted at the end of the meeting. The dimensions of the boards are 90W x 150H cm. Adhesive tape for mounting the posters on the boards will be available at the poster area.

 

Welcome Reception and Banquet

Badges are required for admission.

 

Tour to Knossos and Museum

Busses for the island tour will be leaving from the hotel on Tuesday, May 30 at 2:30 p.m. Accompanying persons will also be picked up at the hotel front lobby at that time. Badges are required for participation.

 

Lunches

Lunches will be served at the indicated times to all registered participants and registered accompanying persons in the hotel. Badges are required for admission. 

 

 

 





Sunday, May 28

 

5:00 - 8:00 PM

Open Registration

 

 

 

8:00 PM

 

Welcome Reception/Dinner

 

 

 

Monday, May 29

 

 

 

8:30 AM

 

Welcome and Opening Remarks

 

 

 

Session I.

Transcription Factors and Signals for the Osteoimmune System: Part 1

 

 

 

9:00 AM

1

Control of cell migration by RANKL

J Penninger

9:30 AM

2

Schnurri-3: a key regulator of postnatal skeletal remodeling

DC Jones, M Wein, and LH Glimcher

10:00 AM

3

Regulation of ectodomain shedding of RANKL

S Tanaka, A Hikita, I Yana, M Seiki, K Nakamura

10:30 AM

4

Regulation of Osteoclast Differentiation and Maturation

Y Choi

 

 

 

11:00 AM

 

Coffee Break & Poster Session

 

 

 

Session II

Transcription Factors and Signals for Osteoclasts

 

 

 

11:30 AM

5

Molecular and cellular pathways in modeled arthritis

E Douni

12:00 Noon

6

Tumor necrosis factor and the osteoclast

S Teitelbaum

12:30 PM

7

Conditional mutagenesis reveals that nfatc1 is required for osteoclast differentiation in vivo

AO Aliprantis, NC Walsh, KP McHugh, E Gravallese, and LH Glimcher

12:45 PM

8

The inositol polyphosphate 4-phosphatase type II, a novel modulator of osteoclast differentiation

J Vacher, M Ferron, and M Pata

1:00 PM

9

ID Helix-loop-helix proteins negatively regulate trance-mediated osteoclasts differentiation

N Kim, J Lee, K Kim, JH Kim, H Mi Jin, HK Choi, SH Lee, Y Yokota, SY Lee, and Y Choi

1:15 PM

10

Osteoclastgenesis is regulated by cyclin-dependent kinase 4/6

Y Murakami, H Takayanagi, N Miyasaka, and H Kohsaka

1:30 PM

11

Signaling pathways mediated by the G protein subunit Gsa are involved in regulation of B lymphopoiesis by osteoblasts

JY Wu, LE Purton, S Rodda, AP McMahon, DT Scadden, and HM Kronenberg

1:45 PM

12

Osteoblasts express members of the NOD family of intracellular pattern recognition receptors that could mediate cell death and inflammation associated with osteomyelitis

I Marriott

2:00 PM

13

Cooperative regulation of bone formation by NFAT and Osterix

T Koga, K Nakashima, and H Takayanagi

 

 

 

2:15 PM

 

Lunch

 

 

 

8:00 PM

 

Dinner at a Local Greek Tavern

 

The bus for the tavern will depart from the hotel at 7:30 PM

 

Tuesday, May 30

 

 

Session III

Bone Metabolism, Hematopoiesis and Immune responses

 

 

 

9:00 AM

14

Immunologic Regulation of Bone Cell Development

M Horowitz

9:30 AM

15

PTH signaling and hematopoiesis

H Kronenberg

10:00 AM

16

Regulation of Hematopoietic Stem Cells in the Osteoblastic Niche

F Arai

10:30 AM

17

The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche

T Nagasawa

 

 

 

11:00 AM

 

Coffee Break, Poster Viewing, and Poster Award Selection

 

 

 

1:30 PM

 

Lunch

 

 

 

2:30 PM

 

Tour to Knossos Archaeological site & Archaeological Museum of Heraklion

The bus for the museum will depart from the hotel at 2:30 PM

 

 

 

8:00 PM

 

Dinner at a local Greek Tavern

 

 

 

Wednesday, May 31

 

 

 

Session IV

Cytokines regulating the crosstalk between bone and the immune system

 

 

 

9:00 AM

18

Identification of osteoclast precursor cells and the role of osteoclasts in anabolic responses to parathyroid hormone

J Lorenzo

9:30 AM

19

Inhibition of osteoclastogenesis by interleukins, lectins and lymphocytes

M Gillespie

10:00 AM

20

Interaction with estrogen receptors as treatment of arthritis and osteoporosis

H Carlsten

10:30 AM

21

Functions of AP-1(Fos/Jun)in inflammatory diseases

E Wagner

 

 

 

11:00 AM

 

Coffee Break

 

 

 

Session V

Costimulation in the immune system and bone

 

 

 

11:30 AM

22

Novel signaling pathways and therapeutic targets in osteoclasts

H Takayanagi

12:00 Noon

23

TREM receptors in osteoimmunology

M Colona

12:30 PM

24

Ligands for TREM2, a regulator of osteoclastogenesis, are expressed on both macrophages and preosteoclasts

MC Nakamura, MB Humphrey, J Hammerman, MR Daws, EC Niemi, LL Lanier, and WE Seaman

12:45 PM

25

An immunoreceptor-like pathway in neutrophils, macrophages and osteoclasts

A Mocsai, MB Humphrey, CL Abram, Z Jakus , Z Kertesz, LL Lanier, MC Nakamura, and CA Lowell

1:00 PM

26

NK cells express RANKL and support osteoclast formation in vitro

S Owen, L Danks, M Feldmann, F Brennan, and NJ Horwood

1:15 PM

27

CD4+ T cells induction of bone destruction during inflammation requires TNFa and not RANKL and is antagonized by IFNg acting in a STAT-1 independent manner via T-bet

MP Quinones, C Estrada, F Jimenez, HG Martinez, M Dudley, OW, RL Reddick, SK Ahuja, and SS Ahuja

1:30 PM

28

B-Lymphocytes are not required for estrogen-mediated effects on bone mineral density

M Lindberg, C Jochems, A Kallkopf, S Windahl, K Pettersson, J Inzunza, J-Å Gustafsson, L Svensson, R Holmdahl, C Ohlsson, and H Carlsten

1:40 PM

29

ALPHA/BETA-T cells do not modulate estrogen deficiency-induced bone loss in rats

RG Erben and K Mildner

1:50 PM

30

The inhibitor of T cell costimulation CTLA-4IG prevents the loss of trabecular and cortical bone loss induced by ovariectomy. Evidence that T-cell activation is required for overiectomy to induce bone loss

F Grassi, Y Gao, M Terauchi, M Ryan, K Page, X Yang, N Weitzmann, and R Pacifici

2:00 PM

 

Discussion for Abstract #28, 29, 30

 

 

 

2:10 PM

 

Lunch

 

 

 

8:00 PM

 

Dinner at Knossos Royal Village

 

 

 

Thursday, June 1

 

 

 

Session VI

Factors regulating the crosstalk between bone and the immune system

 

 

 

9:00 AM

31

Regulation of osteoclastogenesis by inflammatory cytokines and SOCS

A Yoshimura, Y Minoda, H Takaki, and M Ohishi

9:30 AM

32

Role of IKK subunits in osteoclast function and inflammation-induced bone loss

M Karin

 

 

Session VII

Osteoimmune diseases

 

 

 

10:00 AM

33

The role of cell-matrix interactions in osteoclast differentiation and activation

S Goldring

10:30 AM

34

Molecular mechanisms of solid tumor metastases to bone

T Guise

 

 

 

11:00 AM

 

Coffee Break

 

 

 

Session VIII

Novel Therapies

 

 

 

11:30 PM

35

Targeting osteoporosis, inflammation and bone resorption by vaccination against cytokines

MF Bachmann, G Jennings, and G Spohn

12:00 Noon

36

RANKL Inhibition: From Mice to Men (and Women)

D Zack

12:30 PM

37

Apoptotic Osteocytes Induce the Production of pro-inflammatory osteoclastogenic cytokines

G Kogianni, V Mann, and BS Noble

12:45 PM

38

Hyaluronic acid inhibits osteoclast differentiation through toll-like receptor 4

HJ Kim, EJ Chang, J Ha, HJ Kim, J Ryu, UH Kim, ZH Lee, HM Kim, DE Fisher, and HH Kim

1:00 PM

39

Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients

G Brunetti, S Colucci, G Mori, A Oranger, R Rizzi, S Capalbo, V Liso, and M Grano

1:15 PM

40

Novel human RANKL mRNAS are expressed in cell types associated with inflammatory bone loss

NC Walsh, AR Pettit, CA Manning, JF Wang, SR Goldring, KP McHugh, and EM Gravallese

1:30 PM

41

Shwachman-Diamond syndrome is associated with neutropenia and low-turnover primary osteoporosis

S Toiviainen-Salo, M Mäyränpää, N Richards, P Durie, L Ellis, J Rommens, WG Cole, E Savilahti, and O Mäkitie

1:45 PM

42

A neutralizing antibody to sclerostin can increase bone strength and help reduce inflammation induced bone loss

M Robinson, D Marshall, K Greenslade, H Kirby, P Stephens, C Paszty, and A Moore

2:00 PM

43

Molecular and clinical analysis of 200 autosomal recessive osteopetrotic (ARO) patients

C Sobacchi, A Pangrazio, M Helfrich, FP Coxon, PL Poliani, L Susani, F Rucci, P Vezzoni, A Villa, and A Frattini

 

 

 

2:15 PM

 

Concluding Remarks

 

 

 

2:30 PM

 

Lunch

 

 

 

8:00 PM

 

Gala Dinner at Aldemar: Knossos Royal Village

 

Friday, June 2

 

 

 

7:30 AM

 

Breakfast

 

 

 

 

 

Departure

 

POSTERS

 

44

24P3 released from bone enhance progenitor and mature hematopietic cells in bone marrow of transgenic mice

D Costa, R Biticchi, R Tasso, Pennesi, S Negrini, F Descalzi Cancedda, S Garofalo, R Cancedda, and S Tavella

 

45

Association of tumor necrosis factor -a\ G-238A and G-308A promotor polymorphisms with ankylosing spondylitisin Taiwan

MY Shiau, MK Lo, CP Chang, TP Yang, KT Ho, KJ Tsai, and YH Chang

 

46

Bone formation animal models

Y Yu, J-L Yang, B Niechoda, WR Walsh

 

47

Bone phenotype of IL-7 transgenic mice

D Salopek, V Katavic, and V Marusic

 

48

Cytokine expression profile of porcine osteoblasts as determined by flow cytometry

W Sipos, D Krenbek, M Rauner, and P Pietschmann

 

49

Development of bone phenotype in generalised lymphoproliferative disorder

IK Lukic, N Kovacic, D Grcevic, V Katavic, A Lukic, S Ivcevic, and A Marusic

 

50

Distribution of the bone morphogenic protein-4 polymophism in Russian adult women

KA Maslova, MYu Krylov, EE Mikhailov, VA Myakotkin, and LI Benevolenskaya

 

51

Environmental effects on bone matrix and immune function

Zs Valkusz, B Hegedűs, M Radács, Gy Nagyéri, J Gardi, A Juhász, A Petri, and M Gálfi

 

52

FAS/FAS ligand system is important both for apoptosis and differentiation of murine osteoblasts and osteoclasts

N Kovacic, IK Lukic, D Grcevic, V Katavic, P Croucher, and A Marusic

 

53

Features of mandible formation in adult rats after thymectomy

VI Luzin and OV Andrieieva

 

54

Hepatocyte growth factor inhibits BMP-inuced osteoblastogenesis

T Standal, N Abildgaard, UM Fagerli, B Stordal, A Waage, M Borset, and A Sundan

 

55

Heterogeneous expression of HLA class I in Ewing’s Sarcoma cell lines and patients

A de Hooge, G Alblas, S Santos, E Jordanova, A Mulder, C Melief, P Hogendoorn, and A Lankester

 

56

Histological examination of the periodontal tissues in a mouse model periodontal disease

DM Wong, V Tam, R Lam, L Tatarczuch, CN Pagel, RN Pike, NM O’Brien-Simpson, and EJ Mackie

 

57

Identification of RhoGTPases and RhoGEFs up regulated during RANKL-stimulated osteoclastogenesis

A Blangy, N Morrison, H Brazier, S Stephens, P Fort, and S Ory

 

58

IL-23 upregulates RANKL expression from CD4+T cells in IL-1Ra-/- mouse model

JH Ju, ML Cho, YM Moon, S Heon Lee, YO Jung, HJ Ko, and HY Kim

 

59

IL-4, IL-10 and CTLA-4 gene polymorphisms in Taiwanese patients with ankylosing spodylitis

KT Ho, YH Chang, and CM Chen

 

60

Interleukin-1 is a mediator of TNF-induced cartilage and bone damage

J Zwerina, K Polzer, J Gasser, L Joosten, G Kollias, J Smolen, W van den Berg, K Redlich, and G Schett

 

61

Interleukin-18 induces the production of Vascular Endothelial Growth Factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1 dependent pathways

YO Jung, ML Cho, JH Ju,YM Moon, SH Lee, HJ Ko, and HY Kim

 

62

Interleukin-6 and osteoprotegerin systems profiles in an apparently healthy population

I Pantsulaia, S Trofimov, E Kobyliansky, and G Livshits

 

63

Investigating the relationship between bone and immune systems

S Corneau, S Y Smith, and L LeSauteur

 

64

IP-10 mediates bone erosion in collagen-induced arthritis

H Bok Kwak, H Ha, HN Kim, JH Lee, D Yang, HH Kim, YW Song, and Z Hee Lee

 

65

Osteoclast differentiation, survival and morphology in vitro co-culture system

V Nicolin, P Narducci, B Martinelli, and G Zauli

 

66

Peroxynitrite-modified collagen-II induced synthesis of NO and other inflammatory mediators in chondrogenically differentiated mesenchymal progenitor cells: implications for cartilage damage and repair in the diseased human joint

M Whiteman, JS Armstrong, and JT Schantz

 

67

Phenotypic and functional characteristics of immune cells in severe post-menopausal osteoporotic women : preliminary results.

V Breuil, M Ticchioni, J Testa, A Wakkach, JP Breittmaier, CH Roux, C Blin- Wakkach, A Bernard, L Euller-Ziegler, and GF Carle

 

68

RANKL and OPG regulate pro-inflammatory cytokine production in mice

K Maruyama, H Yasuda, and K Matsuo

 

69

RANKL-mediated upregulation of oscar expression is dependent on IKKa

M Chaisson and W Dougall

 

70

Regulation of human osteoclast development by LILRB4 in vitro

Y Mori, M Inui, S Tsuji, A Nakamura, and T Takai

 

71

Regulation of Mouse Osteoprotegerin Gene Expression by Glucocorticoids

T Kondo, R Kitazawa, and S Kitazawa

 

72

Regulation of Osteoclast differentiation and function by CAMK and CREB pathway

A Suematsu, K Sato, and H Takayanagi

 

73

Risk Factors of osteoporosis in Systemic Lupus Erythematosus (SLE) - an Observational Study 
K Almehed, H Forsblad, EG Kvist, C Ohlsson, and H Carlsten

 

74

STAT3 and NF-kB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model, IL-1 receptor antagonist-deficient mice

ML Cho, YO Jung, JH Ju, HJ Ko, SH Lee, YM Moon, HY Kim

 

75

Suppression of Osteoclastogenisis by activated T-lymphocytes does not depend on the mode of their activation

D Grčević, IK Lukić, N Kovačić, S Ivčević, V Katavić, and A Marušić

 

76

The bisphosphonate induces the inflammatory cytokines but inhibits the osteoclastogenesis from the human peripheral blood mononuclear cells (PBMCS) in vitro

W Park, SR Kwon, and JY Shin

 

77

The extrinsic regulation of hematopoietic stem cell function

SR Mayack and AJ Wagers

 

78

Time-Dependent RANKL and OPG gene expression in calvarie- and bone marrow-derived osteoblasts in mouse and rat

M Rauner, E Kallay, M Winzer, and P Pietschmann

 

79

TLR-2, 3, 4 modulate the osteoclastogenic activity of RA FLS via RANKL activation

S Heon Lee, KW Kim, ML Cho, JH Ju, YO Jung, HJ Ko, and HY Kim

 

80

TRANCE-induced Schlafen2 is a positive regulator of osteoclastogenesis

NK Lee, HK  Choi, HJ Yoo, and SY Lee

 

81

Hepatocyte growth factor can substitute for macrophage colony stimulating factor in RANKL induced osteoclatogenesis

IE Adamopoulos, Xia Zhidao, YS Lau, GG Russell, and NA Athanasou

 

82

Estrogen deficiency induces bone loss in mice lacking the ITAM adapter proteins, DAP12 or FcRγ

Y Wu, J Torchia, A Mocsai, CA Lowell, LL Lanier, MC Nakamura, and MB Humphrey

 

83

HMGB1 is a bone and immune-active cytokine

JP Bidwell, J Yang, R Shah, M Charoonpatrapong, and AG Robling

 

84

Murine dentritic cells differentiate in vivo into functional osteoclasts

C Blin-Wakkach, A Wakkach, R Dacquin, P Jurdic, and GF Carle

 

85

Differential cytokine gene expression in the pagetic osteoblast

J Cornish, B Matthews, U Bava, KE Callon, M Black, S Song, GD Gamble, IR Reid, and D Naot

 

86

RANKL inhibition with RANK-fc prevents bone loss but does not affect immune status in a mouse collagen-induced arthritis (CIA) model

WC Dougall, A Armstrong, D Alcorn, A Brewer, J Tocker, and M Chaisson

 

87

The RANKL inhibitor denosumab increases bmd in postmenopausal women with osteopenia or osteoporosis with no alterations in measured parameters of immune function

LA Fitzpatrick, PD Miller, EM Lewiecki, A Wang, Y Liu, DJ Zack, and SB Cohen

 

88

Dietary intervention, does vitamin D intake have anti tumour necrosis factor properties?

L Førli, Ø Bjørtuft, and J Boe

 

89

Continuous PTH treatment causes bone loss through a bidirectional cross-talk between stromal cells and T cells

Y Gao, M Terauchi, F Grassi, MR Ryan, K Page, X Yang, MN Weitzmann, and R Pacifici

 

90

Deficiency of the specific immune system enhances bone healing in-vivo

MS Gaston, BS Noble, and AHRW Simpson

 

91

Oxidized low density lipoproteins induce RANKL production by resting Human T cells.

LS Graham, F Parhami, and RB Effros

 

92

The extracellular matrix proteins, fibronectin and vitronectin, have a biphasic effect on osteoclastogenesis and alter the expression of important osteoclastic markers

A Gramoun, DP Trebec, N Azizi, and MF Manolson

 

93

Heparin Sulphate binding VEGF isoforms selectively enhance endochondral bone formation and regulate the bone marrow hematopoietic stem cell niche

S Bartunkova, C Maes, K Haigh, A Chan, L Liontos, I Stockmans,  K Moermans, R Van Looveren, A Nagy, G Carmeliet, and JJ Haigh

 

94

Protective properties of dexamethasone in experimental postmenopausal osteoporosis

C Jochems, A Kallkopf, M Lindberg, C Ohlsson, and H Carlsten

 

95

Raloxifene is a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis

C Jochems, A Kallkopf, M Lindberg, C Ohlsson, and H Carlsten

 

96

Actions of C-type lectins on bone metabolism

V Kartsogiannis, A Nakamura, H Zhou, C Gange, C Ly, NA Sims, TJ Martin, Kong Wah Ng, JMW Quinn, and MT Gillespie

 

97

Mechanisms of shn3-mediated inhibition of osteoblast function

MN Wein, DC Jones, M Oukka, and LH Glimcher

 

98

RANKL inhibition with rank-fc inhibits osteoclast activity at doses that do not affect host immune responses to influenza infection

RE Miller, D Branstetter, J Jones, L Cowan, and WC Dougall

 

99

Targeting both osteoclast and osteoblast more effectively recudes prostate cancer growth in bone than either alone

KS Mohammad, R Vessella, E Corey, and TA Guise

 

100

Novel role for the immunomodulatory protein PLCγ2 in the regulation of bone homeostasis

R Faccio and D Mao

 

101

Rats overexpressing soluble opg from a prenatal stage exhibit a high bone mass phenotype but no alterations in the development of lymphoid organs or in innate immune response

M Stolina, D Dwyer, MS Ominsky, T Corbin, DJ Zack, G Van, B Bolon, J McCabe, and PJ Kostenuik

 

102

DC-STAMP play a role in osteoclast and macrophage giant cell fusion and dendritic cell cross presentation

T Miyamoto, Y Toyama, and T Suda

 

103

Pathway analysis during osteoblastic/adipocitic differentiation of human bone marrow-derived mesenchymal stem cells for the identification of osteoporosis therapeutic targets

F Zolezzi, S Fenu, C Villa, R Calogero, and P Tarroni

 

104

LTbR-signaling is not required for earliest lymph node developement

MFR Vondenhoff and RE Mebius

 

105

TIRC7, a new marker identifying a subset of CD25lowFoxp3+CD4+ regulatory T cells

A Wakkach, S Augier, J Breittmayer, C Blin-Wakkach, and GF Carle

 

106

Osteoclastic differentiation in two murine cell clones: Expression of neuronal oxide synthase (NOS) isoform and TNF-related apoptosis induced ligand (TRAIL) in osteoclastogenesis

V Nicolin, P Narducci, and G Zauli